144 related articles for article (PubMed ID: 35287976)
21. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
22. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.
Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ
Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028
[TBL] [Abstract][Full Text] [Related]
23. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
[TBL] [Abstract][Full Text] [Related]
24. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
Warren EH; Deeg HJ
Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.
Adhikari J; Gyawali B; Sharma P; Bhatt VR
Future Oncol; 2017 Apr; 13(10):935-944. PubMed ID: 27935324
[TBL] [Abstract][Full Text] [Related]
26. Genomic polymorphism and allogeneic hematopoietic transplantation outcome.
Mullighan CG; Petersdorf EW
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):19-27. PubMed ID: 16399580
[TBL] [Abstract][Full Text] [Related]
27. Innate immunity against hematological malignancies.
Ruggeri L; Capanni M; Tosti A; Urbani E; Posati S; Aversa F; Martelli MF; Velardi A
Cytotherapy; 2002; 4(4):343-6. PubMed ID: 12396834
[TBL] [Abstract][Full Text] [Related]
28. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
29. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
30. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
31. Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation.
Kobayashi S; Kikuta A; Ito M; Sano H; Mochizuki K; Akaihata M; Waragai T; Ohara Y; Ogawa C; Ono S; Ohto H; Hosoya M
Pediatr Blood Cancer; 2014 Oct; 61(10):1880-2. PubMed ID: 24464971
[TBL] [Abstract][Full Text] [Related]
32. Haploidentical hematopoietic cell transplantation.
Koh LP; Chao N
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S60-S63. PubMed ID: 18724305
[TBL] [Abstract][Full Text] [Related]
33. HLA mismatching as a strategy to reduce relapse after alternative donor transplantation.
Fleischhauer K; Beelen DW
Semin Hematol; 2016 Apr; 53(2):57-64. PubMed ID: 27000727
[TBL] [Abstract][Full Text] [Related]
34. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
35. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
36. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing.
Wang A; Li W; Zhao F; Zheng Z; Yang T; Wang S; Yan J; Lan J; Fan S; Zhao M; Shen J; Li X; Yang T; Lu Q; Lu Y; Bai H; Zhang H; Cai D; Wang L; Yuan Z; Jiang E; Zhou F; Song X
Cell Transplant; 2022; 31():9636897221102902. PubMed ID: 35670196
[TBL] [Abstract][Full Text] [Related]
38. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen YH; Wang Y; Han W; Chen H
J Clin Immunol; 2008 May; 28(3):276-83. PubMed ID: 18204965
[TBL] [Abstract][Full Text] [Related]
39. Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Kameda K; Harada K; Saburi M; Okinaka K; Shinohara A; Uchida N; Nishijima A; Ozawa Y; Tanaka M; Kuriyama T; Katayama Y; Sawa M; Ikegame K; Kawakita T; Kanda Y; Nakamae H; Ara T; Kimura T; Sato A; Fukuda T; Atsuta Y; Nakasone H
Transplant Cell Ther; 2022 Apr; 28(4):209.e1-209.e9. PubMed ID: 34995815
[TBL] [Abstract][Full Text] [Related]
40. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]